1. Home
  2. MRSN vs ROMA Comparison

MRSN vs ROMA Comparison

Compare MRSN & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRSN
  • ROMA
  • Stock Information
  • Founded
  • MRSN 2001
  • ROMA 2018
  • Country
  • MRSN United States
  • ROMA Hong Kong
  • Employees
  • MRSN N/A
  • ROMA N/A
  • Industry
  • MRSN Biotechnology: Pharmaceutical Preparations
  • ROMA Savings Institutions
  • Sector
  • MRSN Health Care
  • ROMA Finance
  • Exchange
  • MRSN Nasdaq
  • ROMA Nasdaq
  • Market Cap
  • MRSN 40.7M
  • ROMA 45.3M
  • IPO Year
  • MRSN 2017
  • ROMA 2024
  • Fundamental
  • Price
  • MRSN $0.29
  • ROMA $3.20
  • Analyst Decision
  • MRSN Strong Buy
  • ROMA
  • Analyst Count
  • MRSN 5
  • ROMA 0
  • Target Price
  • MRSN $5.75
  • ROMA N/A
  • AVG Volume (30 Days)
  • MRSN 2.8M
  • ROMA 270.0K
  • Earning Date
  • MRSN 08-12-2025
  • ROMA 08-01-2025
  • Dividend Yield
  • MRSN N/A
  • ROMA N/A
  • EPS Growth
  • MRSN N/A
  • ROMA N/A
  • EPS
  • MRSN N/A
  • ROMA N/A
  • Revenue
  • MRSN $34,006,000.00
  • ROMA $1,029,120.00
  • Revenue This Year
  • MRSN N/A
  • ROMA N/A
  • Revenue Next Year
  • MRSN $1.30
  • ROMA N/A
  • P/E Ratio
  • MRSN N/A
  • ROMA N/A
  • Revenue Growth
  • MRSN N/A
  • ROMA N/A
  • 52 Week Low
  • MRSN $0.26
  • ROMA $0.46
  • 52 Week High
  • MRSN $2.83
  • ROMA $4.14
  • Technical
  • Relative Strength Index (RSI)
  • MRSN 38.23
  • ROMA 58.38
  • Support Level
  • MRSN $0.27
  • ROMA $2.91
  • Resistance Level
  • MRSN $0.36
  • ROMA $3.44
  • Average True Range (ATR)
  • MRSN 0.03
  • ROMA 0.29
  • MACD
  • MRSN -0.01
  • ROMA -0.01
  • Stochastic Oscillator
  • MRSN 16.81
  • ROMA 72.73

About MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage and overcome various business matters arising from such factors related to ESG, sustainability and climate change. it provides tailored-made sustainability solutions to meet the client's specific needs. Its mission is to provide its clients with a one-stop destination for high-quality and holistic sustainability and climate change-related consulting services to support a more sustainable, balanced and inclusive future for its clients' organizations and the world.

Share on Social Networks: